Exelixis layoffs, on the record
Every job cut, severance charge and restructuring Exelixis reported in its annual reports, 2023 to 2026, quoted from the filings. Headcount went from 1,310 to 1,077.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | 1,310 | December 31, 2023 |
| 10-K for 2025 | 1,147 | December 31, 2024 |
| 10-K for 2026 | 1,077 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryExelixis announced and implemented a restructuring plan that reduced its employee workforce.
Word for word“In January 2024, we announced and implemented a restructuring plan, including a reduction of our employee workforce by approximately 175 employees, or 13% of our total headcount.” 10-K for 2023
Our summaryExelixis plans to exit part of its laboratory space in the Greater Philadelphia area as part of the restructuring plan approved in early 2024.
Word for word“We anticipate exiting approximately 40,000 square feet of our laboratory space in the Greater Philadelphia area as part of our restructuring plan approved in early 2024.” 10-K for 2023
Our summaryThe restructuring plan was also intended to reduce real estate commitments and costs and terminate certain licensing partnerships; the accounting impact was still being evaluated.
Word for word“In January 2024, our Board of Directors authorized, and we implemented, a corporate restructuring plan intended to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities, including reducing real estate commitments and costs, and terminating certain licensing partnerships.” 10-K for 2023
Our summaryAnnounced and implemented a restructuring plan that reduced the employee workforce by about 175 employees, or 13% of total headcount.
Word for word“In January 2024, we announced and implemented a restructuring plan, including a reduction of our employee workforce by approximately 175 employees, or 13% of our then total headcount.” 10-K for 2025
Our summaryAuthorized a corporate restructuring plan (the 2024 Restructuring Plan) to reduce workforce and rebalance cost structure, including reducing real estate commitments and terminating certain licensing partnerships.
Word for word“In January 2024, we announced that our Board of Directors had authorized a corporate restructuring plan (the 2024 Restructuring Plan) to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities, including reducing real estate commitments and costs, and terminating certain licensing partnerships.” 10-K for 2025
Our summaryRecorded total restructuring costs under the 2024 Restructuring Plan, including severance and employee-related costs, contract termination costs and impairment.
Word for word“The total restructuring costs, incurred during the year ended December 31, 2024, associated with the 2024 Restructuring Plan were $ 33.7 million and were recorded to the restructuring expense line item within our Consolidated Statements of Income as they were incurred through the end of the plan.” 10-K for 2025
Our summaryExited two leases in the Greater Philadelphia area covering about 40,000 square feet and recognized a non-cash impairment charge.
Word for word“In connection with the restructuring plan, we recognized $ 12.7 million of non-cash impairment charge during the year ended December 31, 2024, to reduce the carrying value of these long-lived assets at their fair value.” 10-K for 2025
Our summaryTerminated certain in-licensing collaboration arrangements as part of the 2024 Restructuring Plan.
Word for word“As part of the 2024 Restructuring Plan (as defined below), we have terminated certain of our in-licensing collaboration arrangements, including Aurigene Oncology, Ltd., BioInvent International AB, Cybrexa Therapeutics LLC, NBE-Therapeutics AG and STORM Therapeutics LTD.” 10-K for 2025
Our summaryIn August 2025 the company adopted and carried out a corporate reorganization plan to reorganize its workforce and close its King of Prussia, Pennsylvania office.
Word for word“In August 2025, our Board of Directors authorized, and we implemented, a corporate reorganization plan (the 2025 Plan) to reorganize our workforce and close our office located in King of Prussia, Pennsylvania.” 10-K for 2026
Our summaryThe 2025 reorganization plan cost $20.5 million in total, mostly severance and employee-related costs, recorded in 2025.
Word for word“The total restructuring costs, incurred during the year ended December 31, 2025, associated with the 2025 Plan were $ 20.5 million and are presented in the restructuring expense line item within our Consolidated Statements of Income.” 10-K for 2026
Our summaryIn January 2024 the company adopted and carried out a restructuring plan to cut its workforce and rebalance its cost structure.
Word for word“In January 2024, our Board of Directors authorized, and we implemented, a corporate restructuring plan (the 2024 Plan) to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities.” 10-K for 2026
Our summaryThe 2024 restructuring plan cost $33.7 million in expenses in 2024.
Word for word“The total restructuring costs, incurred during the year ended December 31, 2024, associated with the 2024 Plan were $ 33.7 million in expenses and were recorded to the restructuring expense line item within our Consolidated Statements of Income as they were incurred through the end of the plan.” 10-K for 2026
Our summaryAs part of the 2024 restructuring plan, the company gave up about 40,000 square feet of office and laboratory space in the Greater Philadelphia area in 2025.
Word for word“In 2025, we exited approximately 40,000 square feet of our office and laboratory space in the Greater Philadelphia area as part of our 2024 corporate restructuring plan.” 10-K for 2026
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-12-31 | $914,000 | $4.6 million |
| 2017-12-29 | −$32,000 | — |
| 2018-12-28 | $0 | — |
| 2022-12-30 | $0 | — |
| 2023-12-29 | $0 | — |
| 2025-01-03 | $33.7 million | — |
| 2026-01-02 | $20.5 million | $17.7 million |
Exelixis filed 1 restructuring notice (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Exelixis’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-10. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.